Abstract 5336: Dissecting the molecular mechanism of trastuzumab resistance in stage IV HER2-positive gastric cancer patients
Qi Xu(Zhejiang Cancer Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing‐Jing Li(Shanghai Institute of Nutrition and Health), Junrong Yan, Jianying Jin(Wenzhou Medical University), Cong Luo(Huazhong University of Science and Technology), Xue Wu, Yang Shao, Hua Bao(Shanghai Jiao Tong University), Haimeng Tang(Unknown), Haimin Weng(Zhejiang Chinese Medical University)
Cited by 0
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412